February 28, 2024
A New York federal judge entered final judgments against medical device company RenovaCare, its controlling shareholder, and its former chief operating officer to settle a U.S. Securities and Exchange Commission suit accusing them of artificially inflating RenovaCare's stock price, ordering them to pay a total of $5.2 million.
October 18, 2023
An ex-executive of RenovaCare and a shareholder have agreed to pay about $3 million to settle a U.S. Securities and Exchange Commission suit accusing them of artificially inflating the stock price of the biotech company.